-
公开(公告)号：US20230293691A1
公开(公告)日：2023-09-21
申请号：US18008911
申请日：2021-06-09
发明人： Lei Xiao , Chengfei Pu , Zhiyuan Cao , Xiaogang Shen , Dongqi Chen , Beibei Jia , Le Tian
IPC分类号： A61K39/00 , C07K16/30 , A61P35/00 , A61P37/04 , C07K14/725 , C07K14/705
CPC分类号： A61K39/464486 , A61K39/4611 , A61K39/4631 , A61P35/00 , A61P37/04 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K16/30 , A61K38/00 , A61K2039/505 , C07K2319/33
摘要： The present disclosure relates to compositions and methods for treating a subject having cancer associated with melanoma-associated antigen 4 (MAGE-A4) peptide. The disclosure includes the embodiments relate to a chimeric antigen receptor (CAR) that binds MAGE-A4 peptide, a polynucleotide encoding a CAR that binds the MAGE-A4 peptide, a modified cell comprising a CAR that binds the MAGE-A4 peptide, and a population of modified cells comprising a CAR that binds the MAGE-A4 peptide.
-
公开(公告)号：US20230201440A1
公开(公告)日：2023-06-29
申请号：US17998127
申请日：2021-05-07
发明人： Lei Xiao , Zhiyuan Cao , Zhao Wu , Chengfei PU , Xiaogang Shen , Haiyang Tang , Le Tian
CPC分类号： A61M1/362 , A61M1/3609 , A61M1/3692 , C07K16/2809 , C07K16/2818 , C12M41/36 , A61M2205/3368 , A61M2205/3324
摘要： The present disclosure relates to a system for immune therapy, the system comprising a sample processing module configured to obtain whole blood from a subject; a cell incubation module configured to activate blood cells of the whole blood and/or introduce a vector into the blood cells of the whole blood; and a cell infusion module configured to infuse at least a portion of the whole blood to the subject, wherein the blood cells comprise CD3+ cells, NK cells, myeloid cells, and neutrophils.
-
公开(公告)号：US20240058337A1
公开(公告)日：2024-02-22
申请号：US18450545
申请日：2023-08-16
发明人： Lei Xiao , Zhao Wu , Chengfei Pu , Zhiyuan Cao , Dongqi Chen , Xiaobin Lu , Le Tian
IPC分类号： A61K31/506 , A61K39/395 , A61K39/00 , A61K31/573 , A61P35/00
CPC分类号： A61K31/506 , A61K39/3955 , A61K39/4631 , A61K31/573 , A61K39/4611 , A61K39/4612 , A61P35/00
摘要： The present disclosure relates to compositions and methods for reducing side effects and/or enhancing cancer treatment that use modified immune cells expressing chimeric antigen receptors (CARs) or modified T cell receptors (TCRs). The modified immune cells, such as T cells or NK cells, can express CARs or TCRs targeting solid tumor antigens, white blood cell antigens like CD19, or bispecific CARs/TCRs targeting both. The methods include administering dasatinib to reduce the side effects associated with CAR T or TCR therapy and/or enhance cancer treatment. The modified cells can co-express additional therapeutic agents like cytokines.
-
公开(公告)号：US20230226113A1
公开(公告)日：2023-07-20
申请号：US18194349
申请日：2023-03-31
发明人： Yang Li , Zhiyuan Cao , Wei Ding , Xianyang Jiang , Chengfei Pu , Le Tian , Christopher Ballas , Zhao Wu , Lei Xiao
IPC分类号： A61K35/17 , A61K47/69 , C07K14/725
CPC分类号： A61K35/17 , A61K47/6911 , C07K14/7051
摘要： The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFNγ.
-
公开(公告)号：US20230074145A1
公开(公告)日：2023-03-09
申请号：US17821706
申请日：2022-08-23
发明人： Zhiyuan Cao , Yuzhe Peng , Lei Xiao , Zhao Wu , Le Tian
IPC分类号： C07K16/40 , C07K14/725 , A61K35/17 , A61P35/00
摘要： The compositions and methods described herein are directed to treating solid tumors using CAR T therapy and/or antibodies targeting GCC. The compositions include CAR comprising an extracellular domain that binds GCC.
-
公开(公告)号：US20240299452A1
公开(公告)日：2024-09-12
申请号：US18441683
申请日：2024-02-14
发明人： Chengfei Pu , Dongqi Chen , Xiaogang Shen , Le Tian
CPC分类号： A61K35/17 , A61K31/436 , A61K39/4612 , A61K39/4613 , A61K39/4631 , A61K39/464411 , A61K39/464441 , A61P35/00 , C07K14/57 , C07K16/2803 , A61K2239/13 , A61K2239/21 , A61K2239/58
摘要： Embodiments of the present disclosure relate to compositions and methods of enhancing anti-tumor activities of modified cells, the method comprising: administering an effective amount of the modified cells to a subject having a solid tumor; and administering an effective amount of an agent to the subject, the agent comprising rapamycin, wherein the modified cells inhibit growth of the solid tumor in the subject, and wherein the anti-tumor activities in the subject are greater than those in a subject that is administered with an effective amount of modified cells but without the agent.
-
公开(公告)号：US20240075061A1
公开(公告)日：2024-03-07
申请号：US18065301
申请日：2022-12-13
发明人： Wensheng Wang , Dongqi Chen , Chengfei Pu , Zhao Wu , Lei Xiao , Zhiyuan Cao , Le Tian
IPC分类号： A61K35/17 , A61K39/00 , A61P35/00 , C12Q1/6886
CPC分类号： A61K35/17 , A61K39/4611 , A61K39/4622 , A61K39/4631 , A61K39/464412 , A61K39/464454 , A61P35/00 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present disclosure relates to compositions and methods for enhancing infiltration of lymphocytes into tumor tissue, enhancing anti-tumor lymphocyte activities in tumor microenvionment (TME), inhibiting regulatory lymphocyte (e.g., B and T cells) activities in TME, and/or long term benefit of cell therapies. For example, in a method of in vivo cell expansion, the method comprises administering an effective amount of cells comprising an antigen binding molecule to a subject; and administering an effective amount of presenting cells expressing a solid tumor antigen that the binding molecule binds.
-
公开(公告)号：US20240024476A1
公开(公告)日：2024-01-25
申请号：US18260376
申请日：2022-01-06
发明人： Chengfei Pu , Zhiyuan Cao , Xiaogang Shen , Wensheng Wang , Beibei Jia , Dongqi Chen , Xiaoqiang Xu , Xudong Tang , Wei Ding , Xianyang Jiang , Yuzhe Peng , Guiting Han , Le Tian , Zhao Wu , Lei Xiao
IPC分类号： A61K39/00 , C07K14/725 , C12N5/0783 , C07K16/30 , C07K16/28 , C07K16/18 , C07K16/40 , A61P35/00
CPC分类号： A61K39/4631 , C07K14/7051 , C12N5/0636 , C07K16/3023 , C07K16/303 , C07K16/2875 , C07K16/2803 , C07K16/28 , C07K16/2851 , C07K16/18 , C07K16/40 , A61P35/00 , A61K39/4611 , A61K39/4644 , A61K39/464474 , A61K39/464417 , A61K39/464402 , A61K39/464458 , A61K39/464411 , C07K2319/03 , C07K2319/33 , C07K2317/622 , A61K2239/13 , C07K2317/31
摘要： The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. For example, the compositions include CAR T cells comprising an extracellular domain that binds FCR1, MSLN, GPC-3, ALPP, CD70, CLDN6, ROR1, CD205, ACPP, ADAM12, or CLDN18.2.
-
公开(公告)号：US20230322899A1
公开(公告)日：2023-10-12
申请号：US18043021
申请日：2021-08-24
发明人： Chengfei Pu , Xiaogang Shen , Zhiyuan Cao , Lei Xiao , Beibei Jia , Le Tian
IPC分类号： C07K14/705 , C07K14/725 , A61K38/21
CPC分类号： C07K14/70578 , C07K14/70521 , C07K14/70503 , C07K2319/03 , A61K38/217 , C07K2319/02 , C07K14/7051
摘要： The present disclosure relates to a fusion protein and uses thereof. For example, the fusion protein comprises an extra-cellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is derived from a first molecule, and the intracellular domain is derived from a second molecule. The first molecule is different from the second molecule, and the second molecule comprises OX40, CD40, 4-1 BB, GITR, ICOS, CD28, CD27, HER2, EGFR, EL-10R, IL-12R, IL-18R1, IL-23R, GP130, or IL-15Ra.
-
公开(公告)号：US11633427B2
公开(公告)日：2023-04-25
申请号：US17592601
申请日：2022-02-04
发明人： Yang Li , Zhiyuan Cao , Wei Ding , Xianyang Jiang , Chengfei Pu , Le Tian , Christopher Ballas , Zhao Wu , Lei Xiao
IPC分类号： A61K35/17 , A61K47/69 , C07K14/725
摘要： The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFNγ.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.035 秒)
